Genetic Immunization
OwnerZane Neal, Hans Herweijerinventors
Life of this patent
Estimating the term…
Abstract
Proper timing and combinatorial administration of immunocytokines and Flt3-L combined with vaccination with tumor associated antigens provides an anticancer therapeutic benefit. Sequential administration of GM-CSF after Flt3-L provides improved expansion of mature dendritic cell populations. The expansion of mature dendritic cells can be used to enhance an immune response in the subject.
Claims13
A method for enhancing an immune response to a tumor in an animal comprising:
- a) administering an effective dose of Fms-like tyrosine kinase ligand (Flt3-L) to the subject;
- b) providing a time interval during which a population of immature dendritic cells is expanded in the subject;
- c) administering, after the time interval of step b), an effective does of granulocyte-monocyte colony stimulating factor (GM-CSF),
- d) administering an effective does of an immunocytokine to the subject;
- and,
- e) administering an effective does of a tumor associated antigen to the subject.
The method of step 1 wherein the time interval consists of about 5 to about 15 days.
The method of step 1 wherein the time interval consists of about 8 to about 12 days.
The method of step 1 wherein administering an effective dose of Flt3-L consists of delivering to the subject purified Flt3-L protein.
The method of step 1 wherein administering an effective dose of Flt3-L consists of delivering to the subject a nucleic acid encoding the Flt3-L.
The method of step 1 wherein administering an effective dose of GM-CSF consists of delivering to the subject purified GM-CSF protein.
The method of step 1 wherein administering an effective dose of GM-CSF consists of delivering to the subject a nucleic acid encoding the GM-CSF.
The method of step 1 wherein administering an effective dose of immunocytokine consists of delivering to the subject purified immunocytokine protein.
The method of step 1 wherein administering an effective dose of immunocytokine consists of delivering to the subject a nucleic acid encoding the immunocytokine.
The method of step 1 wherein administering an effective dose of tumor associated antigen consists of delivering to the subject purified tumor associated antigen protein.
The method of step 1 wherein administering an effective dose of tumor associated antigen consists of delivering to the subject a nucleic acid encoding the tumor associated antigen.
Dependencies are inferred from the claim text.